Shutov A M, Savinova G A, Kiselev L I, Smirnov M N, Iudintseva E V
Klin Med (Mosk). 2002;80(4):54-7.
The study enrolled male patients with fever admitted to Ulyanovsk city hospital in November-December 2000 with diagnosis of hemorrhagic fever with renal syndrome (HFRS). The diagnosis was confirmed serologically. 10 patients received recombinant interleukin 2 (rIL-2) in a dose 250,000 IU/day for 5 days. rIL-2 was not given to 10 control patients. Both groups received intravenous prednisolone in a dose 90 mg/day. The response was assessed by minimal diuresis, maximal serum concentrations of urea and creatinine. No lethal outcomes occurred. Minimal diuresis was higher, creatinine and urea levels lower in patients on rIL-2 (647.0 +/- 268.6 mg/day vs 422.0 +/- 198.2 ml/day, p < 0.05; 221.8 +/- 98.1 mcmol/l vs 398.9 +/- 234.9 mcmol/l, p < 0.05; 14.9 +/- 5.1 mcmol/l vs 22.0 +/- 9.0 mmol/l, p < 0.05). Thus, it is evident that rIL-2 reduces symptoms of acute renal failure in HFRS patients. Further investigations of rIL-2 treatment in HFRS are needed.
该研究纳入了2000年11月至12月期间因肾综合征出血热（HFRS）诊断而入住乌里扬诺夫斯克市医院的发热男性患者。诊断通过血清学确诊。10名患者接受了剂量为250,000 IU/天的重组白细胞介素2（rIL-2），持续5天。10名对照患者未接受rIL-2治疗。两组均接受了剂量为90 mg/天的静脉注射泼尼松龙。通过最小尿量、尿素和肌酐的最大血清浓度评估反应。未发生死亡病例。接受rIL-2治疗的患者最小尿量更高，肌酐和尿素水平更低（647.0±268.6 mg/天对422.0±198.2 ml/天，p<0.05；221.8±98.1 μmol/l对398.9±234.9 μmol/l，p<0.05；14.9±5.1 μmol/l对22.0±9.0 mmol/l，p<0.05）。因此，很明显rIL-2可减轻HFRS患者急性肾衰竭的症状。需要对HFRS患者使用rIL-2治疗进行进一步研究。
